PBT-3, a hepoxilin stable analog, causes long term inhibition of growth of K562 solid tumours in vivo.
Biochem Biophys Res Commun
; 338(1): 158-60, 2005 Dec 09.
Article
em En
| MEDLINE
| ID: mdl-16102726
ABSTRACT
We demonstrate herein that daily administration of PBT-3 for 8 days to NU/NU mice bearing solid tumours derived from the s.c. administration of the leukemic cell line K562 results in inhibition of growth of the tumours in vivo, and this inhibition lasts for 60 days after stopping treatment with PBT-3 before recovery of tumour growth is re-established. Similar findings were observed when the mice were treated with Gleevec (STI-571). These results provide new evidence that PBT-3 is effective in controlling solid tumour growth in vivo and suggest that the PBT family may be useful in the development of new drugs in cancer therapy.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Leucemia Eritroblástica Aguda
/
Ácido 8,11,14-Eicosatrienoico
/
Inibidores do Crescimento
/
Antineoplásicos
Tipo de estudo:
Etiology_studies
Limite:
Animals
/
Female
/
Humans
Idioma:
En
Ano de publicação:
2005
Tipo de documento:
Article